Becton Dickinson & CO 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Becton, Dickinson and Company (BD) reported its Q2 2026 financial results, detailing revenue growth and the impact of its recent spin-off of the Biosciences and Diagnostic Solutions business.
NYSE
Becton, Dickinson and Company reported a 1.6% revenue increase and a 26.1% net income jump in Q1 2026, while completing its Biosciences and Diagnostic Solutions spin-off and planning a $2 billion share repurchase.
NYSE
Becton, Dickinson and Company reported a 10.4% revenue increase in Q3 2025, alongside a strategic plan to combine its Biosciences and Diagnostic Solutions business with Waters Corporation.
NYSE
Becton Dickinson's Q2 2025 revenues increased by 4.5% year-over-year, driven by the Advanced Patient Monitoring acquisition and growth in key segments, while the company progresses with plans to separate its Biosciences and Diagnostic Solutions business.
NYSE
10-Q: Becton Dickinson Reports Q1 2025 Results, Announces Biosciences and Diagnostic Solutions Separation
Becton Dickinson (BD) reports a 9.8% increase in Q1 2025 revenue and announces plans to separate its Biosciences and Diagnostic Solutions business.
NYSE
Becton Dickinson's Q3 2024 results show a revenue increase of 2.3% year-over-year, alongside the announcement of a $4.2 billion acquisition of Edwards Lifesciences' Critical Care product group.
NYSE
Becton Dickinson's Q2 2024 results show a 4.6% revenue increase year-over-year, with growth in Medical and Interventional segments, despite some headwinds in China.
NYSE
Becton, Dickinson and Company (BD) reported a 2.6% increase in revenue for the first quarter of fiscal year 2024, while facing challenges from market dynamics in China and increased costs.